Managing Clinical Trials in the Cloud

By Bruce Maches

August 24, 2010

In earlier posts I provided an overview of the various phases of the drug approval process. In a nutshell this consists of drug discovery, development, and testing. Across all of these phases various clinical trails are performed to test the drugs effects on people and how well the effectiveness of the drug. 

These clinical trails that are a part of the overall drug development process consist of 3 distinct types:

Phase I Clinical Development (Human Pharmacology) – Thirty days after a biopharmaceutical company has filed its IND, it may begin a small-scale Phase I clinical trial unless the FDA places a hold on the study. Phase I studies are used to evaluate pharmacokinetic parameters and tolerance, generally in healthy volunteers.  These studies include initial single-dose studies, dose escalation and short-term repeated-dose studies.

Phase II Clinical Development (Therapeutic Exploratory) – Phase II clinical studies are small-scale trials to evaluate a drug’s preliminary efficacy and side-effect profile in 100 to 250 patients.  Additional safety and clinical pharmacology studies are also included in this category.

Phase III Clinical Development (Therapeutic Confirmatory) – Phase III studies are large-scale clinical trials for safety and efficacy in large patient populations. While phase III studies are in progress, preparations are made for submitting the Biologics License Application (BLA) or the New Drug Application (NDA).  BLAs are currently reviewed by the FDA’s Center for Biologics Evaluation and Research (CBER).  NDAs are reviewed

While the logistics of all types of trials are very similar, Phase III trials represent the most time consuming and expensive one of the three. These types of trials are meant to provide proof to the FDA on the actual effectiveness of the drug and can require thousands of test subjects and take years to complete. Out of the entire drug development process a significant portion of the expense is incurred in completing the Phase III tests.

Here is a brief synopsis of some of the issues and tasks involved in executing long term Phase III clinical trials:

  • Protocol design – creating the overall design of the trial as to patient profiles, drug dosage, administration, tracking of patients, data capture, managing adverse events or side effects reporting, trial supply chain management
  • Enrolling patients – in many cases thousands of patients are required to be involved in the trial to get the information required to obtain FDA approval
  • Complex logistics – scheduling all of the patient visits and getting the test supplies and drug products to the research centers for administration to patients
  • Geographically disperse – most trails are held in multiple locales with many companies are now performing clinical trials overseas
  • Expensive – as mentioned before it can cost tens to hundreds of millions of dollars to complete a Phase III trial
  • Time consuming – trials can run for years especially for drugs to be taken continuously for chronic disease conditions
  • Patient data security – ensuring the security and integrity of the patients personal and health information
  • Data access – providing appropriate and secure access to the data for the scientists, researchers and primary investigators
  • Data management – all trials create large amounts of data including Case Report Forms (CRF’s) where the results of each patient interaction are recorded
  • Regulatory compliance – ensuring that the supporting systems and processes meet both 21 CFR Part 11 and HIPAA regulatory compliance guidelines

To support large scale clinical trials, the life science CIO has to deal with the challenges of provisioning and supporting the necessary hardware and software infrastructure. While there are a number of applications on the market for managing clinical trials many life science companies are looking to cloud based offerings to reduce the complexity along with the time and expense for performing these trials. 

Several companies are stepping into this space and providing cloud based SaaS applications that can drastically cut the time and costs required to put into place the systems and processes required to support the clinical trial process. Software companies, such as Cmed with their eClinical system, ClinPlus with their CTM application and Clinical Systems with their Clinical Trials Management Software package. To alleviate concerns about putting patient data in the public cloud many vendors are providing their applications via a private cloud where security, validation and data protection can be ensured and to only allow access to properly trained users as part of their Part 11 compliance efforts.

These cloud based clinical trails applications provide a number of advantages:

– No need to provision hardware and provide associated infrastructure

– Data security and disaster recovery are built in

– FDA compliance is a part of the overall environment

– Support and maintenance of the system is provided by the vendor

– Many of these systems are quickly configurable so that new trials and associated protocols can be quickly defined and made ready for use

– Centralized control of the entire environment

– Easier access for the sharing of data and results

By utilizing cloud based applications to facilitate phase 3 clinical trials life science CIO’s can drastically reduce both costs and time required to get new medications to market.

 

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

Ohio Supercomputer Center Dedicates ‘Owens’ Cluster

March 29, 2017

In a dedication ceremony held earlier today (March 29), officials from Ohio Supercomputer Center (OSC) along with state representatives gathered to celebrate the launch of OSC’s newest cluster: Read more…

By Tiffany Trader

EU Ratchets up the Race to Exascale Computing

March 29, 2017

The race to expand HPC infrastructure, including exascale machines, to advance national and regional interests ratcheted up a notch yesterday with announcement that seven European countries – Read more…

By John Russell

Data-Hungry Algorithms and the Thirst for AI

March 29, 2017

At Tabor Communications’ Leverage Big Data + EnterpriseHPC Summit in Florida last week, esteemed HPC professional Jay Boisseau, chief HPC technology strategist at Dell EMC, engaged the audience with his presentation, “Big Computing, Big Data, Big Trends, Big Results.” Read more…

By Tiffany Trader

Bill Gropp – Pursuing the Next Big Thing at NCSA

March 28, 2017

About eight months ago Bill Gropp was elevated to acting director of the National Center for Supercomputing Applications (NCSA). Read more…

By John Russell

HPE Extreme Performance Solutions

Leveraging the Power of Big Data to Improve Customer Satisfaction & Brand Loyalty

In the dynamic world of retail, retailers must find ways to recognize and effectively respond to shopping behaviors, patterns, and trends in order to succeed. Read more…

UK to Launch Six Major HPC Centers

March 27, 2017

Six high performance computing centers will be formally launched in the U.K. later this week intended to provide wider access to HPC resources to U.K. Read more…

By John Russell

AI in the News: Rao in at Intel, Ng out at Baidu, Nvidia on at Tencent Cloud

March 26, 2017

Just as AI has become the leitmotif of the advanced scale computing market, infusing much of the conversation about HPC in commercial and industrial spheres, it also is impacting high-level management changes in the industry. Read more…

By Doug Black

Scalable Informatics Ceases Operations

March 23, 2017

On the same day we reported on the uncertain future for HPC compiler company PathScale, we are sad to learn that another HPC vendor, Scalable Informatics, is closing its doors. Read more…

By Tiffany Trader

‘Strategies in Biomedical Data Science’ Advances IT-Research Synergies

March 23, 2017

“Strategies in Biomedical Data Science: Driving Force for Innovation” by Jay A. Etchings is both an introductory text and a field guide for anyone working with biomedical data. Read more…

By Tiffany Trader

Data-Hungry Algorithms and the Thirst for AI

March 29, 2017

At Tabor Communications’ Leverage Big Data + EnterpriseHPC Summit in Florida last week, esteemed HPC professional Jay Boisseau, chief HPC technology strategist at Dell EMC, engaged the audience with his presentation, “Big Computing, Big Data, Big Trends, Big Results.” Read more…

By Tiffany Trader

Bill Gropp – Pursuing the Next Big Thing at NCSA

March 28, 2017

About eight months ago Bill Gropp was elevated to acting director of the National Center for Supercomputing Applications (NCSA). Read more…

By John Russell

HPC Compiler Company PathScale Seeks Life Raft

March 23, 2017

HPCwire has learned that HPC compiler company PathScale has fallen on difficult times and is asking the community for help or actively seeking a buyer for its assets. Read more…

By Tiffany Trader

Quantum Bits: D-Wave and VW; Google Quantum Lab; IBM Expands Access

March 21, 2017

For a technology that’s usually characterized as far off and in a distant galaxy, quantum computing has been steadily picking up steam. Read more…

By John Russell

Trump Budget Targets NIH, DOE, and EPA; No Mention of NSF

March 16, 2017

President Trump’s proposed U.S. fiscal 2018 budget issued today sharply cuts science spending while bolstering military spending as he promised during the campaign. Read more…

By John Russell

CPU-based Visualization Positions for Exascale Supercomputing

March 16, 2017

In this contributed perspective piece, Intel’s Jim Jeffers makes the case that CPU-based visualization is now widely adopted and as such is no longer a contrarian view, but is rather an exascale requirement. Read more…

By Jim Jeffers, Principal Engineer and Engineering Leader, Intel

US Supercomputing Leaders Tackle the China Question

March 15, 2017

Joint DOE-NSA report responds to the increased global pressures impacting the competitiveness of U.S. supercomputing. Read more…

By Tiffany Trader

New Japanese Supercomputing Project Targets Exascale

March 14, 2017

Another Japanese supercomputing project was revealed this week, this one from emerging supercomputer maker, ExaScaler Inc., and Keio University. The partners are working on an original supercomputer design with exascale aspirations. Read more…

By Tiffany Trader

For IBM/OpenPOWER: Success in 2017 = (Volume) Sales

January 11, 2017

To a large degree IBM and the OpenPOWER Foundation have done what they said they would – assembling a substantial and growing ecosystem and bringing Power-based products to market, all in about three years. Read more…

By John Russell

Quantum Bits: D-Wave and VW; Google Quantum Lab; IBM Expands Access

March 21, 2017

For a technology that’s usually characterized as far off and in a distant galaxy, quantum computing has been steadily picking up steam. Read more…

By John Russell

Trump Budget Targets NIH, DOE, and EPA; No Mention of NSF

March 16, 2017

President Trump’s proposed U.S. fiscal 2018 budget issued today sharply cuts science spending while bolstering military spending as he promised during the campaign. Read more…

By John Russell

HPC Compiler Company PathScale Seeks Life Raft

March 23, 2017

HPCwire has learned that HPC compiler company PathScale has fallen on difficult times and is asking the community for help or actively seeking a buyer for its assets. Read more…

By Tiffany Trader

TSUBAME3.0 Points to Future HPE Pascal-NVLink-OPA Server

February 17, 2017

Since our initial coverage of the TSUBAME3.0 supercomputer yesterday, more details have come to light on this innovative project. Of particular interest is a new board design for NVLink-equipped Pascal P100 GPUs that will create another entrant to the space currently occupied by Nvidia's DGX-1 system, IBM's "Minsky" platform and the Supermicro SuperServer (1028GQ-TXR). Read more…

By Tiffany Trader

Tokyo Tech’s TSUBAME3.0 Will Be First HPE-SGI Super

February 16, 2017

In a press event Friday afternoon local time in Japan, Tokyo Institute of Technology (Tokyo Tech) announced its plans for the TSUBAME3.0 supercomputer, which will be Japan’s “fastest AI supercomputer,” Read more…

By Tiffany Trader

IBM Wants to be “Red Hat” of Deep Learning

January 26, 2017

IBM today announced the addition of TensorFlow and Chainer deep learning frameworks to its PowerAI suite of deep learning tools, which already includes popular offerings such as Caffe, Theano, and Torch. Read more…

By John Russell

Lighting up Aurora: Behind the Scenes at the Creation of the DOE’s Upcoming 200 Petaflops Supercomputer

December 1, 2016

In April 2015, U.S. Department of Energy Undersecretary Franklin Orr announced that Intel would be the prime contractor for Aurora: Read more…

By Jan Rowell

Leading Solution Providers

Is Liquid Cooling Ready to Go Mainstream?

February 13, 2017

Lost in the frenzy of SC16 was a substantial rise in the number of vendors showing server oriented liquid cooling technologies. Three decades ago liquid cooling was pretty much the exclusive realm of the Cray-2 and IBM mainframe class products. That’s changing. We are now seeing an emergence of x86 class server products with exotic plumbing technology ranging from Direct-to-Chip to servers and storage completely immersed in a dielectric fluid. Read more…

By Steve Campbell

Enlisting Deep Learning in the War on Cancer

December 7, 2016

Sometime in Q2 2017 the first ‘results’ of the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C) will become publicly available according to Rick Stevens. He leads one of three JDACS4C pilot projects pressing deep learning (DL) into service in the War on Cancer. Read more…

By John Russell

BioTeam’s Berman Charts 2017 HPC Trends in Life Sciences

January 4, 2017

Twenty years ago high performance computing was nearly absent from life sciences. Today it’s used throughout life sciences and biomedical research. Genomics and the data deluge from modern lab instruments are the main drivers, but so is the longer-term desire to perform predictive simulation in support of Precision Medicine (PM). There’s even a specialized life sciences supercomputer, ‘Anton’ from D.E. Shaw Research, and the Pittsburgh Supercomputing Center is standing up its second Anton 2 and actively soliciting project proposals. There’s a lot going on. Read more…

By John Russell

HPC Startup Advances Auto-Parallelization’s Promise

January 23, 2017

The shift from single core to multicore hardware has made finding parallelism in codes more important than ever, but that hasn’t made the task of parallel programming any easier. Read more…

By Tiffany Trader

HPC Technique Propels Deep Learning at Scale

February 21, 2017

Researchers from Baidu’s Silicon Valley AI Lab (SVAIL) have adapted a well-known HPC communication technique to boost the speed and scale of their neural network training and now they are sharing their implementation with the larger deep learning community. Read more…

By Tiffany Trader

US Supercomputing Leaders Tackle the China Question

March 15, 2017

Joint DOE-NSA report responds to the increased global pressures impacting the competitiveness of U.S. supercomputing. Read more…

By Tiffany Trader

CPU Benchmarking: Haswell Versus POWER8

June 2, 2015

With OpenPOWER activity ramping up and IBM’s prominent role in the upcoming DOE machines Summit and Sierra, it’s a good time to look at how the IBM POWER CPU stacks up against the x86 Xeon Haswell CPU from Intel. Read more…

By Tiffany Trader

IDG to Be Bought by Chinese Investors; IDC to Spin Out HPC Group

January 19, 2017

US-based publishing and investment firm International Data Group, Inc. (IDG) will be acquired by a pair of Chinese investors, China Oceanwide Holdings Group Co., Ltd. Read more…

By Tiffany Trader

  • arrow
  • Click Here for More Headlines
  • arrow
Share This